Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FTRE
stocks logo

FTRE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
663.75M
-4.77%
0.165
-8.19%
659.17M
+1.21%
0.113
+463.7%
678.16M
-4.53%
0.195
+2.76%
Estimates Revision
The market is revising Upward the revenue expectations for Fortrea Holdings Inc. (FTRE) for FY2025, with the revenue forecasts being adjusted by 3.53% over the past three months. During the same period, the stock price has changed by 24.68%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.53%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.78%
In Past 3 Month
Stock Price
Go Up
up Image
+24.68%
In Past 3 Month
Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 11.19 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 11.19 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
7 Hold
2 Sell
Hold
Current: 14.500
sliders
Low
7.00
Averages
11.19
High
14.00
Current: 14.500
sliders
Low
7.00
Averages
11.19
High
14.00
Citi
Patrick Donnelly
Neutral
maintain
$10 -> $12
2025-11-10
Reason
Citi
Patrick Donnelly
Price Target
$10 -> $12
2025-11-10
maintain
Neutral
Reason
Citi analyst Patrick Donnelly raised the firm's price target on Fortrea to $12 from $10 and keeps a Neutral rating on the shares.
Mizuho
Ann Hynes
Neutral
maintain
$9 -> $11
2025-11-07
Reason
Mizuho
Ann Hynes
Price Target
$9 -> $11
2025-11-07
maintain
Neutral
Reason
Mizuho analyst Ann Hynes raised the firm's price target on Fortrea to $11 from $9 and keeps a Neutral rating on the shares.
Evercore ISI
Elizabeth Anderson
In Line
maintain
$11 -> $14
2025-11-06
Reason
Evercore ISI
Elizabeth Anderson
Price Target
$11 -> $14
2025-11-06
maintain
In Line
Reason
Evercore ISI analyst Elizabeth Anderson raised the firm's price target on Fortrea to $14 from $11 and keeps an In Line rating on the shares. The company's transition under new leadership is off to a promising start as the Q3 book-to-bill ratio held steady despite management changes, reflecting both internal focus and an improving demand landscape, the analyst tells investors in a research note. The firm added that while the stock's rapid quarter-to-date rise keeps it cautious, the market's potential improvement into 2026 could prompt a re-evaluation.
Mizuho
Neutral
maintain
$7 -> $9
2025-10-17
Reason
Mizuho
Price Target
$7 -> $9
2025-10-17
maintain
Neutral
Reason
Mizuho raised the firm's price target on Fortrea to $9 from $7 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also "cautiously optimistic" that contract research organization trends have bottomed.
Jefferies
Hold
maintain
$7
2025-09-09
Reason
Jefferies
Price Target
$7
2025-09-09
maintain
Hold
Reason
Jefferies raised the firm's price target on Fortrea to $9.50 from $7 and keeps a Hold rating on the shares. Biotech funding was stronger in the last three months and bookings improved across the contract research organization industry, the analyst tells investors in a research note. However, Jefferies believes recent demand signals "are still equally mixed."
Baird
Eric Coldwell
Outperform
upgrade
$9 -> $14
2025-09-03
Reason
Baird
Eric Coldwell
Price Target
$9 -> $14
2025-09-03
upgrade
Outperform
Reason
Baird analyst Eric Coldwell raised the firm's price target on Fortrea to $14 from $9 and keeps an Outperform rating on the shares. The firm updated its model following its meeting with the new CEO and Investor Relations team.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fortrea Holdings Inc (FTRE.O) is 21.65, compared to its 5-year average forward P/E of 26.73. For a more detailed relative valuation and DCF analysis to assess Fortrea Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
26.73
Current PE
21.65
Overvalued PE
42.77
Undervalued PE
10.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.51
Undervalued EV/EBITDA
9.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.67
Current PS
0.00
Overvalued PS
0.99
Undervalued PS
0.36
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 105.42% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 182.65% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 105.42% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

FTRE News & Events

Events Timeline

(ET)
2025-12-04
07:10:00
SCTbio and Fortrea Sign Strategic Collaboration Agreement
select
2025-11-24 (ET)
2025-11-24
07:09:57
Fortrea Finalizes $75.7 Million Tender Offer for Senior Notes
select
2025-11-17 (ET)
2025-11-17
07:12:32
Fortrea names Gallagher as General Counsel
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04Globenewswire
SCTbio and Fortrea Forge Strategic Partnership to Accelerate Cell Therapy Development
  • Strategic Agreement: SCTbio and Fortrea have signed a strategic collaboration agreement aimed at integrating clinical trials with GMP manufacturing to shorten the development timeline for cell therapies, thereby accelerating the market entry of advanced therapies.
  • Resource Integration Advantage: This partnership combines Fortrea's global clinical reach with SCTbio's expertise in cell therapy and viral vector manufacturing, creating a more efficient supply chain that enhances the safety and speed of therapy delivery.
  • Development Process Optimization: The two companies will work together to optimize the pathway from early-stage development to first-in-human trials, ensuring seamless alignment in planning and execution for cell and gene therapy projects, which will enhance overall project success rates.
  • Setting Industry Benchmarks: By uniting Fortrea's extensive development experience with SCTbio's manufacturing capabilities, this collaboration aims to establish new operational excellence standards in advanced therapy development, driving overall industry progress.
[object Object]
Preview
7.0
12-03Globenewswire
Cytokinetics Faces Shareholder Investigation Over Alleged Misstatements
  • Shareholder Investigation Initiated: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders to seek corporate reforms and fund recovery, highlighting potential governance risks within the company.
  • FDA Review Delay: On May 1, 2025, Cytokinetics announced that the FDA extended the review date for aficamten's NDA from September 26, 2025, to December 26, 2025, indicating compliance issues that could undermine future market confidence.
  • Impact of Misstatements: Company executives acknowledged that they submitted the NDA without including a Risk Evaluation and Mitigation Strategy (REMS), leading to misleading statements about the company's prospects, which could result in significant financial harm to shareholders.
  • Potential Legal Consequences: These misleading statements may expose Cytokinetics to lawsuits and liability, further impacting its stock price and market reputation, underscoring deficiencies in the company's transparency and compliance practices.
[object Object]
Preview
7.0
12-01Globenewswire
Crucial Update for Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Fortrea Holdings, Inc. (NASDAQ: FTRE), Ibotta, Inc. (NYSE: IBTA), and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Looking into Claims for You

  • Cytokinetics Investigation: Grabar Law Office is investigating claims against Cytokinetics, Inc. for potential breaches of fiduciary duties by its officers and directors, following allegations of misleading statements regarding the FDA's review process for their drug aficamten, which harmed shareholders.

  • Fortrea Holdings Investigation: Shareholders of Fortrea Holdings, Inc. are being investigated for claims of misleading statements about the company's financial prospects and operations, which allegedly inflated their earnings targets and misrepresented the viability of their business model.

  • Ibotta Investigation: Grabar Law Office is looking into claims against Ibotta, Inc. for misleading investors during its IPO regarding the risks associated with its contract with Kroger, which was at-will and could be terminated without notice, potentially impacting the company's revenue.

  • WEBTOON Entertainment Investigation: A class action lawsuit against WEBTOON Entertainment Inc. has survived a motion to dismiss, with allegations that the company misrepresented its Monthly Active Users and failed to disclose adverse trends affecting its business prior to its IPO.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fortrea Holdings Inc (FTRE) stock price today?

The current price of FTRE is 14.5 USD — it has decreased -0.55 % in the last trading day.

arrow icon

What is Fortrea Holdings Inc (FTRE)'s business?

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

arrow icon

What is the price predicton of FTRE Stock?

Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 11.19 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fortrea Holdings Inc (FTRE)'s revenue for the last quarter?

Fortrea Holdings Inc revenue for the last quarter amounts to 701.30M USD, increased 3.91 % YoY.

arrow icon

What is Fortrea Holdings Inc (FTRE)'s earnings per share (EPS) for the last quarter?

Fortrea Holdings Inc. EPS for the last quarter amounts to -0.17 USD, decreased -45.16 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fortrea Holdings Inc (FTRE)'s fundamentals?

The market is revising Upward the revenue expectations for Fortrea Holdings Inc. (FTRE) for FY2025, with the revenue forecasts being adjusted by 3.53% over the past three months. During the same period, the stock price has changed by 24.68%.
arrow icon

How many employees does Fortrea Holdings Inc (FTRE). have?

Fortrea Holdings Inc (FTRE) has 15500 emplpoyees as of December 05 2025.

arrow icon

What is Fortrea Holdings Inc (FTRE) market cap?

Today FTRE has the market capitalization of 1.34B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free